U.S. markets closed

Ionis Pharmaceuticals, Inc. (IONS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
37.78+0.09 (+0.24%)
At close: 4:00PM EDT
38.25 +0.47 (1.24%)
After hours: 07:27PM EDT
Full screen
Loading interactive chart...
  • 3 Stocks Wall Street Thinks Will Skyrocket 50% or More
    Motley Fool

    3 Stocks Wall Street Thinks Will Skyrocket 50% or More

    Here are three stocks that Wall Street thinks will skyrocket 50% or more. Ionis Pharmaceuticals (NASDAQ: IONS) has been a big loser so far this year with shares sinking 34%. The average price target for Ionis reflects a 56% premium above the current share price.

  • Ionis' Chief Scientific Officer C. Frank Bennett, Ph.D., receives Gabbay Award in Biotechnology and Medicine
    PR Newswire

    Ionis' Chief Scientific Officer C. Frank Bennett, Ph.D., receives Gabbay Award in Biotechnology and Medicine

    Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that Executive Vice President and Chief Scientific Officer C. Frank Bennett, Ph.D., is a co-recipient of the 23rd Jacob and Louise Gabbay Award in Biotechnology and Medicine for his innovative work on antisense therapy. Established in 1998, the Gabbay Award recognizes scientists in academia, medicine or industry whose work has had outstanding scientific content and significant practical consequences in the biomedical sciences. The award,

  • Ionis' antisense therapies in ATTR amyloidosis to be featured at 2021 PNS Annual Meeting
    PR Newswire

    Ionis' antisense therapies in ATTR amyloidosis to be featured at 2021 PNS Annual Meeting

    Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, today announced that multiple presentations highlighting advances in its ATTR amyloidosis programs will be featured during the 2021 Peripheral Nerve Society (PNS) Annual Meeting to be held virtually on June 12-13, and 25-27, 2021. Ionis' participation highlights the advancements it's made in developing novel antisense therapies for ATTR and underscores Ionis' commitment to this patient community.